Hexarelin
Educational information only — not medical advice. Many listed compounds are not FDA-approved for human use. Consult a licensed clinician before starting, changing, or stopping any protocol.
Overview
Hexarelin is a synthetic hexapeptide — a chain of six amino acids — that belongs to the growth hormone releasing peptide (GHRP) family. It was developed as an analog of GHRP-6 and is studied for its ability to stimulate a strong, pulsatile release of growth hormone from the pituitary gland.
Among the classic GHRPs, hexarelin is often described as one of the more potent for triggering a growth hormone pulse. Much of the available evidence comes from animal studies and early human research; it has not been approved by any major regulator for therapeutic use.
A recurring theme in the literature is desensitization: the growth hormone response to hexarelin has been reported to diminish with prolonged, continuous administration. For this reason it is commonly discussed in the context of cycling on and off rather than uninterrupted use.
How it works
Hexarelin acts on growth hormone secretagogue receptors in the hypothalamus and pituitary gland, prompting the release of growth hormone. Notably, preclinical work has shown it can stimulate growth hormone release even in cells that do not respond to growth hormone releasing hormone (GHRH), suggesting GHRPs and GHRH work through distinct pathways.
Beyond the growth hormone axis, researchers have reported interest in hexarelin’s effects on cardiac tissue in animal models, which appear to involve mechanisms partially independent of growth hormone, including the CD36 scavenger receptor. These cardiac findings remain preclinical and are not established in humans.
Reported benefits
- Strong, pulsatile stimulation of growth hormone release (animal and early human data)
- Studied for cardioprotective effects in animal models of ischemia and heart injury (preclinical)
- Investigated as a diagnostic tool for probing pituitary growth hormone reserve
These are reported and studied effects, not guaranteed outcomes.
Considerations & side effects
The most frequently discussed limitation of hexarelin is desensitization — a progressive blunting of the growth hormone response with sustained continuous use — which is one reason clinical development of the compound was not carried further. Because robust long-term human safety data is lacking, its overall safety profile is not well characterized.
Reported side effects across GHRPs are generally described as mild and can include injection-site irritation, transient increases in appetite, water retention, and effects on other hormones such as cortisol and prolactin. Product purity varies in the research-chemical market, and hexarelin is not a substitute for evaluation and treatment by a qualified clinician.
Frequently asked
What is Hexarelin?
A synthetic hexapeptide (six amino acids) in the growth hormone releasing peptide (GHRP) family, studied primarily in animals and early human trials as a potent stimulator of growth hormone release.
Is Hexarelin FDA-approved?
No. Hexarelin has been investigated in research settings but is not approved by the FDA or any major regulator for human therapeutic use, and is sold for research purposes only.
How is Hexarelin different from other GHRPs?
It is considered one of the more potent GHRPs for triggering a growth hormone pulse, but studies report that its effect can diminish with prolonged continuous use, which is why it is commonly cycled on and off.
Why is Hexarelin often cycled?
Research suggests the growth hormone response to hexarelin can attenuate (desensitize) with sustained daily exposure, so it is frequently discussed in the context of on-and-off cycling rather than continuous use.
References
- Deghenghi R, et al. GH-releasing activity of Hexarelin, a new growth hormone releasing peptide, in infant and adult rats. ↗
- Giustina A, et al. Hexarelin, a novel GHRP-6 analog, stimulates GH release in a GH-secreting rat cell line insensitive to GH-releasing hormone. ↗
- Fernández-Fernández M, et al. Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects. ↗
- Huang J, et al. The Growth Hormone Secretagogue Hexarelin Protects Rat Cardiomyocytes From in vivo Ischemia/Reperfusion Injury Through Interleukin-1 Signaling Pathway. ↗
Related compounds
Recombinant human growth hormone. Used for GH deficiency, anti-aging, and body composition optimization. Requires careful dosing and monitoring via bloodwork.
Long-acting analog of insulin-like growth factor 1 with extended half-life. Promotes muscle growth, recovery, and cellular repair. More potent than native IGF-1.
A synthetic growth-hormone-releasing peptide (ghrelin-receptor agonist) that stimulates pituitary GH secretion via a pathway distinct from GHRH. The original GHRP from which ipamorelin was later derived; typically pulsed subcutaneously, often stacked with a GHRH.